Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Total stock-based compensation expense	$ 4,419	$ 4,814
Lucid Diagnostics Inc [Member]
Total stock-based compensation expense	3,208	3,835
Cost Of Revenue [Member]
Total stock-based compensation expense	23
Selling and Marketing Expense [Member]
Total stock-based compensation expense	444	625
General and Administrative Expense [Member]
Total stock-based compensation expense	3,588	4,002
Research and Development Expense [Member]
Total stock-based compensation expense	364	187
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Cost Of Revenue [Member]
Total stock-based compensation expense	12
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	223	265
Lucid Diagnostics Inc 2018 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	2,512	3,201
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	70	71
PAVmed Inc 2014 Equity Plan [Member] | Cost Of Revenue [Member]
Total stock-based compensation expense	7
PAVmed Inc 2014 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	133	175
PAVmed Inc 2014 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	156	68
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	$ 95	$ 55